Skip to main content

Table 1 Threshold dose prices for various vaccination strategies, considering a two-dose schedule

From: Assessing the cost-effectiveness of HPV vaccination strategies for adolescent girls and boys in the UK

Vaccination strategy

£, versus halted vac. (3.5%)

£, versus girls’ vac. (3.5%)

£, versus halted vac. (1.5%)

£, versus girls’ vac. (1.5%)

Girls, bivalent

55.80 (55.04 – 56.57)

-

687.47 (675.62 – 699.20)

-

Girls, quadrivalent

99.64 (98.90 – 100.37)

-

752.46 (740.51 – 764.72)

-

Girls, nonavalent

108.05 (107.36 – 108.75)

-

811.44 (801.18 – 821.68)

-

Girls & boys, bivalent

25.08 (24.64 – 25.52)

-5.67 (-6.42 – -4.93)

361.99 (356.09 – 367.85)

36.46 (26.82 – 45.98)

Girls & boys, quadrivalent

48.38 (47.95 – 48.80)

-2.92 (-3.64 – -2.18)

398.68 (392.65 – 404.84)

44.70 (35.42 – 53.81)

Girls & boys, nonavalent

52.77 (52.42 – 53.10)

-2.56 (-3.13 – -1.99)

429.26 (422.98 – 435.44)

46.88 (37.63 – 56.46)

  1. Mean values shown over 500 simulations, with 95% confidence intervals in brackets. All strategies assume a £20,000 cost-effectiveness threshold for a QALY, with both 3.5% and 1.5% discount rates applied, and a £10 administration charge per dose. When comparing a strategy to girls-only vaccination the same vaccine is used for correct comparison